Yan Xie

Yan Xie

Auto-generated profile, based on publicly available information

Yan Xie

Sichuan University West China Hospital

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2021 in BMJ Open
Verified
Journal Article
Open access
PDF file
LWLixiang Wang
Lixiang Wang
YXYan Xie
Yan Xie
YDYingping Deng
Yingping Deng
Objectives To investigate dry eye disease (DED) in patients affected by systemic lupus erythematosus (SLE). Methods We conducted a systematic search of the literature on PubMed, EMBASE and the Cochrane Library databases from conception to 30 April 2020 for studies related to dry eye, secondary Sjögren’s syndrome (sSS) and SLE. Original full-text articles with the number of patients diagnosed with SLE of over 15 were included. The risk of bias was evaluated with a validated critical appraisal tool which assessed study quality based on confounding factors, selection bias, bias related to measurement and bias related to data analysis. Data were extracted and pooled to evaluate the overall prevalence of DED with the random-effect model and sSS with the fixed effect model. Results A total of 29 studies were included and 18 273 participants were involved. The pooled data showed that the overall prevalence of DED was 16% (95% CI 10% to 21%, p<0.001) in patients of SLE. Dry eye symptoms and abnormal Schirmer’s test were found in 26% (95% CI 20% to 32%, p<0.001) and 24% (95% CI 14% to 34%, p<0.001) of patients with SLE, respectively. 12% (95% CI 9% to 15%, p<0.001) of patients also met the criteria of sSS. The OR of DED in patients with SLE was 4.26 (95% CI 3.47 to 5.05, p<0.001) compared with healthy controls. The meta-regression analysis showed that the sample size (p=0.004) and study location (p=0.022) could be the source of heterogeneity. Conclusions DED and sSS are both common in patients with SLE.



10 October 2017 in Molecular Medicine Reports
Verified
Journal Article
Open access
PDF file
TZTing Zhao
Ting Zhao
JBJun Bai
Jun Bai
QZQingyun Zou
Qingyun Zou
Feng ChenFeng Chen
Feng Chen
YXYan Xie
Yan Xie
Drug resistance is an obstacle to effective treatment of ovarian cancer. There have been substantial evidences supporting the association between diabetes and the sensitivity to chemotherapy. Insulin (INS) is believed to be the strongest, most lasting hypoglycemic drug. Therefore, the present study aimed to elucidate whether insulin could facilitate the anti‑proliferative activities of cisplatin (cis‑diamminedichloroplatinum, DDP) in the A2780 ovarian cancer cell line. The inhibitory effects of DPP with/without INS on the growth of A2780 cells was measured by MTT assay. The cell cycle stages and levels of apoptosis were determined by flow cytometry. The amounts of signaling elements involved in the regulation of were examined using western blotting and reverse transcription‑quantitative polymerase chain reaction analysis. The results indicated that INS pre‑treatment enhanced the inhibitory effect of DDP on the proliferation of A2780 cells, and facilitated the apoptosis induced by DDP. INS‑DDP treatment led to a marked decrease in the percentage of G0/G1 phase cells, but a corresponding increase in the proportion of S phase cells. Furthermore, A2780 cells pretreated with INS followed by DDP upregulated the protein expression level of phosphorylated c‑Jun N‑terminal kinase (JNK), which resulted in a substantial increase in the expression levels of p53 mRNA and protein, compared with DDP administration alone. In conclusion, the combination of INS and DDP facilitated the apoptosis of A2780 cells, which may be associated with the activation of the JNK signaling pathway and consequently the involvement of p53 at both mRNA and protein expression levels. These results may be useful in furthering our understanding of the mechanisms involved in the chemotherapeutic treatment of ovarian cancer.

18 October 2023 in International Journal of Rheumatic Diseases
Verified
Journal Article
Closed access
YXYan Xie
Yan Xie
YLYang Liu
Yang Liu
YQYunhe Qin
Yunhe Qin
XCXiaoyuan Chen
Xiaoyuan Chen
QXQibing Xie
Qibing Xie

17 August 2020 in Research Square
Verified
Preprint
Open access
PDF file
YXYan Xie
Yan Xie
YLYang Liu
Yang Liu
YLYi Liu
Yi Liu
Objectives. To investigate whether prophylactic use of glucocorticoids (GCs) would affect the incidence of postoperative delirium (POD)/cognitive dysfunction (POCD) after major surgeries. Methods. A systemic review of randomized controlled trials (RCTs) searched from the Pubmed, Cochrane Library, Embase, and Clinical Trials.gov was conducted. Effect of GCs on the incidence of POD/POCD and several secondary outcomes, including s100-β, mechanical ventilation time, length of ICU stay, length of postoperative hospital stay, postoperative cardiac arrhythmia, and adverse outcomes, were analyzed. The Cochrane Collaboration’s risk of bias tool and the GRADE system were used to assess the risk of bias of included studies and the evidence quality of combined results, respectively. Results. There were 726 records detected and only 11 studies were included at last. Six of the 11 RCT studies were categorized as low risk of bias, 3 studies as unclear, and 2 as high. Prophylactic use of GCs didn’t show any significant effect on the incidence of POD/POCD after major surgeries, but the evidence quality of this result was very low. For the secondary outcome, GCs can significantly decrease the level of s100-β, length of ICU stay, length of postoperative hospital stay, and ventilation time, with the evidence quality varied from very low to moderate. For the rest of the secondary outcomes, no significant effect was observed. Conclusion. Prophylactic use of GCs didn’t have a significant effect on the incidence of POD and POCD. However, this result was very uncertain, and more relevant high-quality RCTs are needed.